As filed with the Securities and Exchange Commission on January 30, 2013
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 13-4087132 |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
750 Lexington Avenue
New York, New York 10022
(212) 531-5965
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
James F. Oliviero
Chief Financial Officer
Keryx Biopharmaceuticals, Inc.
750 Lexington Avenue
New York, New York 10022
(212) 531-5965
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
The Commission is requested to send copies of all communications to:
Mark F. McElreath
Alston & Bird LLP
90 Park Avenue
New York, New York 10016-1387
Telephone: (212) 210-9595
Approximate date of commencement of proposed sale to the public: As soon as possible after the registration statement becomes effective.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x (File No. 333-171517)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the state offering. ¨ ______
If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. x
If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check, the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange Act of 1934.
Large accelerated filer | ¨ | Accelerated filer | x | |
Non-accelerated filer | ¨ | Smaller reporting company | ¨ | |
(Do not check if a smaller reporting company |
CALCULATION OF REGISTRATION FEE
Title
of Each Class Of Securities To Be Registered |
Amount to be registered | Proposed Maximum Per Share |
Proposed
Maximum Aggregate Offering Price (1) |
Amount of Registration Fee (2) |
Common Stock, $0.001 par value per share | N/A | N/A | $13,392,660.90 | $1,826.76 |
(1) | The $13,392,660.90 proposed maximum aggregate offering price is in addition to the remaining proposed maximum aggregate offering price registered pursuant to the Registrant’s Registration Statement on Form S-3 (File No. 333-171517) | |
(2) | Calculated in accordance with Rule 457(o). |
THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE UPON FILING WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE 462(B) UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE OF
EARLIER REGISTRATION STATEMENT
This Registration Statement is being filed with respect to the registration of additional securities pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Act”), and General Instruction IV of Form S-3. The contents of the Registration Statement on Form S-3 (Registration No. 333-171517) initially filed by Keryx Biopharmaceuticals, Inc. with the Securities and Exchange Commission (the “Commission”) on January 3, 2011, including certain exhibits thereto, and declared effective by the Commission on January 28, 2011, are incorporated herein by reference.
The Company hereby certifies that the filing fee associated with this Registration Statement in the amount of $1,826.76 will be paid to the Commission on January 31, 2013.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of New York, State of New York, on January 30, 2013.
KERYX BIOPHARMACEUTICALS, INC. | |
By: | /s/ James F. Oliviero |
James F. Oliviero Chief Financial Officer, Treasurer and Corporate Secretary |
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated as of January 30, 2013.
Signatures | Title |
/s/ Ron Bentsur* Ron Bentsur
|
Chief Executive Officer and Director |
/s/ James F. Oliviero James F. Oliviero
|
Chief Financial Officer, Treasurer and Corporate Secretary |
/s/ Kevin J. Cameron* Kevin J. Cameron
|
Director |
/s/ Joseph Feczko, M.D.* Joseph Feczko, M.D.
|
Director |
/s/ Wyche Fowler, Jr.* Wyche Fowler, Jr.
|
Director |
/s/ Jack Kaye* Jack Kaye
|
Director |
/s/ Michael P. Tarnok* Michael P. Tarnok
|
Director |
*By: James F. Oliviero James F. Oliviero Attorney-in-Fact
|
EXHIBIT INDEX
Exhibit Number |
Description | |
5.1 | Opinion of Alston & Bird LLP. | |
23.1 | Consent of UHY LLP. | |
23.2 | Consent of Alston & Bird LLP (included in Exhibit 5.1). | |
24.1 | Power of Attorney (filed with the Registration Statement on Form S-3 (File No. 333-171517)). |